Novo Nordisk’s new Wegovy pill hit the market this week. The Danish drug maker, best known for GLP-1 injections like Ozempic and Wegovy, is now the first company to manufacture and receive FDA approval for an oral GLP-1 pill for weight management.

The FDA-approved weight loss drug offers an oral alternative to invasive injections with similar effectiveness.

Novo Nordisk’s daily oral pill, which starts at 1.5 milligrams, will be available for $149 a month for self-paying patients, while a 4 milligram dose will be available for the same price until April 15 of this year, then will rise to $199 a month, according to the company’s website.